News
Amgen eyes pancreatic cancer use for its pathfinder KRAS dru...
Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its
